Search
forLearn
5 / 801 resultslearn multipeptides
learn Beta Polypeptide
learn Pea peptides
learn HMI-115
much-hyped research compound targeting prolactin receptor in scalp
Research
5 / 416 resultsresearch Technology development of herbal remedies for androgenic alopecia external application
The best way to make a topical treatment for hair loss is to mix Saw Palmetto extract with 48% ethanol at the end of making the lotion.
research Development of the composition of the gel base for treating telogen effluvium
The best gel to treat a type of hair loss has 1% sodium alginate, 1% carbopol, 5% glycerin, 0.2% potassium sorbate, and water.
research Absorption sites of orally administered drugs in the small intestine
Different factors affect where drugs are absorbed in the small intestine, which is important for effective medication use.
research Intestinal Permeability Study of Minoxidil: Assessment of Minoxidil as a High Permeability Reference Drug for Biopharmaceutics Classification
Minoxidil works well as a high permeability reference drug for biopharmaceutics classification.
research Development and ex-vivo skin permeation studies of finasteride–poly(lactic acid-co-glycolic acid) and minoxidil–chitosan nanoparticulate systems
Nanoparticles show potential for controlled release of hair loss drugs, improving treatment effectiveness.
Community Join
5 / 1000+ resultscommunity HMI-115: What We Know So Far. HMI-115 (also known as BAY1158061) is a new pharmaceutical drug developed by a biopharmaceutical company called Bioinvent and licensed by Bayer
HMI-115 is a new drug developed by Bioinvent and licensed by Bayer, with mixed opinions on its potential effectiveness. Some users are skeptical and prefer proven treatments like Minoxidil, finasteride, and RU58841.
community Amplifica Sees Positive Results for Hair Loss Treatment - Results Show 15% increase in 60 days!
Amplifica's new injectable treatment for androgenetic alopecia shows a 15% increase in hair thickness and coarseness in 60 days. The treatment is in early human trials and offers a promising alternative to hormone-related hair loss treatments.
community Phase II for Technoderma Therepeutic's TDM-105795 set to begin in April tentatively
Phase II for TDM-105795 for Androgenic Alopecia is set to begin in April 2023. The study aims to evaluate the efficacy and safety of TDM-105795 in male subjects.
community How Veradermics secured a total of $220 million in series B and C financing for oral minoxidil, I will never understand.....
Veradermics' oral minoxidil shows promise for hair regrowth, with some users reporting significant improvements, while Pelage's PP405 results are less convincing and lack transparency. There is skepticism about both treatments' long-term effectiveness and potential side effects.
community Amplifica’s AMP-303 Study Unveils New Hope for Hair Loss Treatments
AMP-303, a new injectable treatment for androgenetic alopecia, showed promising results in increasing hair count and density with minimal side effects. The treatment demonstrated significant hair regrowth and durability, offering new hope for those with hair loss.